Loading...
Loading...
Eli Lilly and Company
LLY today announced its detailed results for the
Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with
mild-to-moderate Alzheimer's disease. This announcement follows the
presentation of results from independent analyses of the EXPEDITION study data
conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic
research consortium, at the annual meeting of the American Neurological
Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and
the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of
Medicine. Dr. Doody is a member of the steering committee for the ADCS.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in